Immunome annual return on equity
2020
2021
2022
2023
2024
2025
Immunome Return on Equity (ROE) Growth & History (IMNM)
Immunome's return on equity was −52.09% for fiscal 2025.
View full Immunome company overviewImmunome annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −52.09% | +142.54 pp |
| 2024 | 2024-12-31 | −194.63% | −38.18 pp |
| 2023 | 2023-12-31 | −156.45% | −42.64 pp |
| 2022 | 2022-12-31 | −113.81% | −58.61 pp |
| 2021 | 2021-12-31 | −55.20% | +569.02 pp |
| 2020 | 2020-12-31 | −624.22% | — |
Immunome quarterly return on equity
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −13.13% | +1.93 pp |
| Q1 2026 | 2026-03-31 | −8.80% | +8.25 pp |
| Q4 2025 | 2025-12-31 | −15.56% | +24.96 pp |
| Q3 2025 | 2025-09-30 | −21.55% | −1.46 pp |
| Q2 2025 | 2025-06-30 | −15.06% | −1.66 pp |
| Q1 2025 | 2025-03-31 | −17.06% | +46.82 pp |
| Q4 2024 | 2024-12-31 | −40.52% | +106.56 pp |
| Q3 2024 | 2024-09-30 | −20.10% | +36.28 pp |
| Q2 2024 | 2024-06-30 | −13.39% | +34.51 pp |
| Q1 2024 | 2024-03-31 | −63.88% | −35.89 pp |
| Q4 2023 | 2023-12-31 | −147.09% | −107.90 pp |
| Q3 2023 | 2023-09-30 | −56.38% | −24.40 pp |
| Q2 2023 | 2023-06-30 | −47.91% | −21.72 pp |
| Q1 2023 | 2023-03-31 | −27.99% | −0.90 pp |
| Q4 2022 | 2022-12-31 | −39.19% | −23.94 pp |
| Q3 2022 | 2022-09-30 | −31.98% | −18.60 pp |
| Q2 2022 | 2022-06-30 | −26.19% | −15.55 pp |
| Q1 2022 | 2022-03-31 | −27.08% | −17.24 pp |
| Q4 2021 | 2021-12-31 | −15.25% | — |
| Q3 2021 | 2021-09-30 | −13.38% | — |
| Q2 2021 | 2021-06-30 | −10.64% | — |
| Q1 2021 | 2021-03-31 | −9.84% | — |
Immunome return on equity trends
Over the last five fiscal years, Immunome's return on equity increased from −624.22% to −52.09%, a change of +572.13 percentage points. The latest reported quarter, Q2 2026, shows −13.13%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immunome source filings ↗